Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Change in Cash (2023 - 2024)

Sagimet Biosciences has reported Change in Cash over the past 2 years, most recently at -$80.8 million for Q2 2024.

  • Quarterly results put Change in Cash at -$80.8 million for Q2 2024, down 1409.85% from a year ago — trailing twelve months through Jun 2024 was $4.3 million (changed N/A YoY), and the annual figure for FY2025 was -$40.8 million, down 5922.97%.
  • Change in Cash for Q2 2024 was -$80.8 million at Sagimet Biosciences, down from $101.6 million in the prior quarter.
  • Over the last five years, Change in Cash for SGMT hit a ceiling of $101.6 million in Q1 2024 and a floor of -$99.8 million in Q4 2023.